Skip to main content

Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.

Publication ,  Journal Article
Samsa, GP; Kolotkin, RL; Williams, GR; Nguyen, MH; Mendel, CM
Published in: Am J Manag Care
September 2001

OBJECTIVES: To determine whether (1) patients who experience greater weight loss also experience correspondingly greater improvements in health-related quality of life (HRQOL); (2) the improvement in HRQOL is noticeable for patients achieving moderate (5%-10%) weight reduction; and (3) the relationship between weight reduction and HRQOL is similar for patients receiving sibutramine hydrochloride vs placebo. STUDY DESIGN: We combined data from 4 double-blind, randomized, controlled trials of administration of sibutramine (20 mg/d) vs placebo. PATIENTS AND METHODS: Patients (n = 555) were mildly to moderately obese and had type 2 diabetes mellitus, dyslipidemia, or hypertension that was well controlled with an angiotensin-converting enzyme inhibitor or calcium channel blocker. The HRQOL was operationalized using the Impact of Weight on Quality of Life (IWQOL) and the Medical Outcomes Study 36-Question Short-Form (SF-36) instruments. The main statistical technique was a patient-level analysis of variance predicting change in HRQOL from study, treatment, and weight change. RESULTS: Moderate weight loss was associated with a statistically significant improvement in HRQOL for approximately half of the subscales evaluated (P < .05). The greatest sensitivity to change was shown by the SF-36 general health perception and change in health since last year subscales and the IWQOL overall health, mobility, and total subscales. Greater weight loss was associated with the most improvement in HRQOL. Weight losses of 5.01% to 10.00% were associated with 2-unit changes in the SF-36 general health perception subscale and 10-unit changes in the IWQOL total subscale. Results were similar across study and treatment. CONCLUSIONS: Moderate weight loss is associated with noticeably improved HRQOL. Improvements in HRQOL are achievable by patients receiving sibutramine.

Duke Scholars

Published In

Am J Manag Care

ISSN

1088-0224

Publication Date

September 2001

Volume

7

Issue

9

Start / End Page

875 / 883

Location

United States

Related Subject Headings

  • Weight Loss
  • United States
  • Randomized Controlled Trials as Topic
  • Quality of Life
  • Placebos
  • Obesity
  • Middle Aged
  • Male
  • Humans
  • Health Policy & Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Samsa, G. P., Kolotkin, R. L., Williams, G. R., Nguyen, M. H., & Mendel, C. M. (2001). Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manag Care, 7(9), 875–883.
Samsa, G. P., R. L. Kolotkin, G. R. Williams, M. H. Nguyen, and C. M. Mendel. “Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo.Am J Manag Care 7, no. 9 (September 2001): 875–83.
Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manag Care. 2001 Sep;7(9):875–83.
Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manag Care. 2001 Sep;7(9):875–883.

Published In

Am J Manag Care

ISSN

1088-0224

Publication Date

September 2001

Volume

7

Issue

9

Start / End Page

875 / 883

Location

United States

Related Subject Headings

  • Weight Loss
  • United States
  • Randomized Controlled Trials as Topic
  • Quality of Life
  • Placebos
  • Obesity
  • Middle Aged
  • Male
  • Humans
  • Health Policy & Services